Regeneron Unveils Key Oncology Pipeline Updates at ESMO 2025, Highlighting Patient-Centric Approaches for Hard-to-Treat Cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its oncology…
CVS Pharmacy Finalizes Nationwide Acquisition of Rite Aid and Bartell Drugs Assets, Expanding Access to Care Across the U.S. CVS Pharmacy, a subsidiary of CVS Health, today announced the successful…
Sanofi Establishes Montpellier as the Global Hub for Translational Research in Autoimmune Diseases Sanofi has announced the launch of a Translational Center of Excellence in Montpellier, a first-of-its-kind initiative developed…
Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside…
Novo Nordisk Acquires Global Rights to Omeros’ MASP-3 Inhibitor Zaltenibart in $2.1 Billion Agreement Novo Nordisk and Omeros Corporation (Nasdaq: OMER) have entered into a definitive asset purchase and license…
WHO Warns of Global Neurological Health Crisis: Over 11 Million Deaths Annually Demand Urgent Action The World Health Organization (WHO) has issued a stark warning about the growing global burden…
WHO and European Union Join Forces to Advance Digital Health Systems Across Sub-Saharan Africa The World Health Organization (WHO) and the European Union (EU) have formally announced a new collaboration…
WHO Medical Product Alert N°5/2025: Identification of Substandard (Contaminated) Oral Liquid Medicines in the South-East Asia Region The World Health Organization (WHO) has issued Medical Product Alert N°5/2025 concerning the…
WHO Launches EIOS 2.0 to Strengthen Global Health Intelligence and Threat Detection The World Health Organization (WHO) today announced the official launch of version 2.0 of its Epidemic Intelligence from…
AbbVie to Present Comprehensive Data on Antibody-Drug Conjugate Portfolio at ESMO 2025, Reinforcing Leadership in Targeted Solid Tumor Therapies AbbVie (NYSE: ABBV) announced today that it will present a robust…
AbbVie Announces FDA Approval of Updated RINVOQ® (upadacitinib) Indication for Inflammatory Bowel Disease NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food…
LEQEMBI® IQLIK™ Named One of TIME’s Best Inventions of 2025 for Transforming Alzheimer’s Treatment Access Eisai Co., Ltd. and Biogen Inc. today announced that LEQEMBI® IQLIK™ (lecanemab-irmb), the first subcutaneous…